Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of PCV-free Liquid Rotarix vs Lyophilised Rotarix in Infants
NCT02914184Phase 3Completed
- Sponsor
- GSK
- Start
- Oct 2016
- Primary completion
- Jun 2018
- Modality
- Live Attenuated Vaccines
- Countries
- 8
01
Overview
Phase 3, randomised, single-blind trial of rotavirus vaccine, live, oral in rotavirus gastroenteritis (4 arms), sponsored by GSK. Primary endpoints: Anti-Rota Virus (Anti-RV) Immunoglobulin A (IgA) Antibody Concentrations, Percentage of Seroconverted Subjects With RV Antibody Concentrations Above or Equal to Cut-off Value and 1 more. Started Oct 2016; status: completed.
02
Drugs
rotavirus vaccine, live, oral
03
Conditions
rotavirus gastroenteritis
Beyond the preview
Go deeper on NCT02914184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02914184.